Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could ritalin help Parkinson's patients walk better?

NCT ID NCT00914095

Symptom relief Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether high doses of methylphenidate (Ritalin) could improve walking and attention in 69 people with advanced Parkinson's disease who still had severe gait problems despite standard treatments. Participants received either methylphenidate or a placebo for three months. The researchers measured walking speed, freezing episodes, and attention to see if the drug helped.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
methylphenidate (Ritalin/Concerta)
What this could lead to
If successful, this could offer a new option to improve walking and attention in advanced Parkinson's patients who still struggle despite standard treatments.
What could go wrong
This is a small, completed phase 4 trial with only 69 participants. Results may not apply to all Parkinson's patients, and methylphenidate can cause side effects like increased heart rate or psychiatric issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

69 people

The number who actually took part.

Start date

Oct 2009

Finished

Dec 2011

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Parkinson's disease of more than 5 years * Subthalamic nucleus stimulation * Gait disorders impeding moderately to severely the activities of daily living * gait disorders including freezing of gait * able to walk without physical assistance Exclusion Criteria: * Dementia (MMSE \< 27 et score de Mattis \< 130) * Requiring dopatherapie modification * Requiring subthalamic stimulation parameters adaptation * Psychiatric disorders: hallucinations, unstable thymic disorders, psychosis) * Cardiac disorders: dysrhythmia or unstable arterial hypertension * Unstable or severe medical illness * intolerance or contraindication to methylphenidate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dementia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dementia Gait Disorders, Neurologic Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dementia Gait disorders, neurologic Parkinson's disease

Contacts and locations

Locations

  • Service de Neurologie, Clinique Neurologique, EA 2683, IFR 114

    Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.